相关实验视频
Updated: May 29, 2025

06:51
A Patient-Derived Xenograft Model for Venous Malformation
Published on: June 15, 2020
5.3K
关于遗传性出血性长长膜病变的病变发生和治疗方法的最新信息
Alka Yadav1,2, Zahra Shabani1,2, Jasneet Kaur Dhaliwal1,2
1Center for Cerebrovascular Research, University of California, San Francisco, San Francisco, CA, United States.
Current vascular pharmacology
|February 4, 2025
概括
遗传性出血性长膜症 (HHT) 涉及错误的TGF-β信号传递,导致异常的血管生长. 本综述涵盖了了解HHT机制的最新进展,并为这种罕见的血管疾病开发新疗法.
科学领域:
- 血管生物学 血管生物学
- 遗传学 是一个遗传学.
- 罕见疾病 罕见疾病
背景情况:
- 遗传性出血性长膜炎 (HHT),或奥斯勒-韦伯-伦杜综合征,是一种遗传性血管疾病.
- 它的特点是动脉静脉形形 (AVMs) 和粘膜皮肤电脉切开.
- 大多数HHT病例源于转化生长因子-β (TGF-β) 途径 (例如,ENG,ACVRL1,SMAD4) 中的基因哈普洛缺陷.
研究的目的:
- 审查了解HHT病变的最新进展.
- 讨论HHT治疗开发的进展.
- 突出血管新生在HHT发育中的作用.
主要方法:
- 关于过去10年发表的研究的文献综述.
- 对HHT背后的遗传和分子机制的分析.
- 在HHT模型和患者中对抗血管生成策略的评估.
主要成果:
- 在阐明HHT疾病机制方面取得了重大进展.
- 了解TGF-β信号通路基因的作用至关重要.
- 抗血管生成策略显示出潜力,但需要进一步研究.
结论:
- 尽管取得了进展,但HHT中telangiectasia和AVM形成的精确机制需要进一步澄清.
- 准TGF-β通路和血管生成对HHT治疗有希望.
- 持续的研究对于改善HHT治疗开发至关重要.
相关概念视频
Esophageal Varices-II: Clinical Features and Management
37
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
37
Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
X-linked Traits
53.1K
In most mammalian species, females have two X sex chromosomes and males have an X and Y. As a result, mutations on the X chromosome in females may be masked by the presence of a normal allele on the second X. In contrast, a mutation on the X chromosome in males more often causes observable biological defects, as there is no normal X to compensate. Trait variations arising from mutations on the X chromosome are called “X-linked”.
53.1K
Mechanism of Angiogenesis
5.2K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
5.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
601
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
601
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
131
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
131

